Now people think these are vanity drugs
Spark Therapeutic, for example cures retinal diseases, genetic mutations, rare diseases, and so we said, Lets try to do this with a drug, or at least a system of a drug thats approved. So we packaged up those three genes, we put them under the control of an antibiotic, doxycyline, and now we could put them into the eye, or anywhere really, and then turn the genes on when we wanted to, to ask the following: if we damage the retina or the optic nerve, and then turn on our reprogramming and make the eye young, well, first of all, does it become young
doi: 10.1111/dom.14890 67
Set a weekly recurring reminder on your phone, smartwatch, or calendar app
Esto se traduce en: Mayor resistencia: puedes aguantar entrenamientos ms largos antes de sentirte agotado
The broader GLP-1 class also remains under active legal scrutiny: more than 4,400 lawsuits have been filed against Eli Lilly and Novo Nordisk in multidistrict litigation alleging failure to warn about gastroparesis and vision loss linked to existing semaglutide and tirzepatide products, though neither orforglipron nor retatrutide is named in that litigation